Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.07% | -40.51% | 120.51% | 119.17% | 104.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.07% | -40.51% | 120.51% | 119.17% | 104.13% |
| Cost of Revenue | 21.55% | 25.27% | 31.76% | 34.56% | 23.91% |
| Gross Profit | -46.71% | -144.27% | 14.80% | 14.49% | 24.38% |
| SG&A Expenses | -4.96% | -2.52% | 2.56% | 4.31% | 8.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.38% | 18.48% | 24.29% | 26.64% | 19.82% |
| Operating Income | -23.81% | -74.40% | 8.82% | 7.74% | 12.78% |
| Income Before Tax | -20.73% | -71.81% | 6.31% | 6.60% | 13.38% |
| Income Tax Expenses | -66.67% | -75.00% | -83.33% | -80.00% | 0.00% |
| Earnings from Continuing Operations | -19.68% | -69.26% | 7.82% | 7.85% | 13.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.68% | -69.26% | 7.82% | 7.85% | 13.24% |
| EBIT | -23.81% | -74.40% | 8.82% | 7.74% | 12.78% |
| EBITDA | -24.24% | -76.76% | 9.64% | 9.15% | 13.73% |
| EPS Basic | -39.02% | -35.07% | 25.36% | 21.06% | 21.42% |
| Normalized Basic EPS | -11.75% | -48.38% | 29.85% | 25.94% | 27.56% |
| EPS Diluted | -39.02% | -35.07% | 25.36% | 21.09% | 21.45% |
| Normalized Diluted EPS | -11.75% | -48.38% | 29.85% | 25.94% | 27.56% |
| Average Basic Shares Outstanding | 18.57% | 20.58% | 21.84% | 17.14% | 12.34% |
| Average Diluted Shares Outstanding | 18.69% | 20.58% | 21.84% | 17.14% | 12.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |